"Vaccines, Conjugate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
| Descriptor ID |
D018074
|
| MeSH Number(s) |
D20.215.894.865.900 D23.050.865.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Conjugate".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Conjugate".
This graph shows the total number of publications written about "Vaccines, Conjugate" by people in this website by year, and whether "Vaccines, Conjugate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 3 | 3 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 3 | 4 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 3 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Conjugate" by people in Profiles.
-
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study. Pediatrics. 2023 Jul 01; 152(1).
-
Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines. Pediatrics. 2022 12 01; 150(6).
-
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis. 2023 02; 23(2):233-246.
-
Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine. JAMA Netw Open. 2022 Mar 01; 5(3):e221111.
-
Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J. 2021 10 01; 40(10):944-951.
-
Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):141-150.
-
Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review. Hum Vaccin Immunother. 2021 05 04; 17(5):1432-1441.
-
Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: Results from a phase 3, randomized trial. Vaccine. 2021 03 05; 39(10):1534-1543.
-
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J. 2020 08; 39(8):763-770.
-
Safety of MenACWY-CRM vaccine exposure during pregnancy. Vaccine. 2020 03 10; 38(12):2683-2690.